Skip to main content

Mind Medicine

corporate_fare Company Profile

Mind Medicine

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed MNMD - Latest Insights

MNMD
Jan 12, 2026, 8:24 AM EST
Filing Type: 8-K
Importance Score:
8